Tomoko Suzuki

Dapagliflozin Reduces Fat Mass without Affecting Muscle Mass in Type 2 Diabetes

Seigo Sugiyama, Hideaki Jinnouchi, Noboru Kurinami et al. · Journal of Atherosclerosis and Thrombosis · 2017 · 103 citations · Full text

The SGLT2 Inhibitor Dapagliflozin Significantly Improves the Peripheral Microvascular Endothelial Function in Patients with Uncontrolled Type 2 Diabetes Mellitus

Seigo Sugiyama, Hideaki Jinnouchi, Noboru Kurinami et al. · Internal Medicine · 2018 · 76 citations · Full text

Liraglutide, a Glucagon-Like Peptide-1 Analog, Increased Insulin Sensitivity Assessed by Hyperinsulinemic-Euglycemic Clamp Examination in Patients with Uncontrolled Type 2 Diabetes Mellitus

Hideaki Jinnouchi, Seigo Sugiyama, Akira Yoshida et al. · Journal of Diabetes Research · 2015 · 54 citations · Full text

Renoprotective Effects of Additional SGLT2 inhibitor Therapy in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease Stages 3b-4: A Real World Report From A Japanese Specialized Diabetes Care Center

Seigo Sugiyama, Hideaki Jinnouchi, Akira Yoshida et al. · Journal of Clinical Medicine Research · 2019 · 26 citations · Full text

Elevation of the renal threshold for glucose is associated with insulin resistance and higher glycated hemoglobin levels

Kunio Hieshima, Seigo Sugiyama, Akira Yoshida et al. · Journal of Diabetes Investigation · 2019 · 25 citations · Full text